Skip to content
QurAlisQurAlis
  • About UsExpand
    • About QurAlis
    • People
    • Partners & Investors
    • Contact Us
  • PlatformExpand
    • Antisense Oligonucleotides
    • Patient-derived disease models
    • References
  • ALS ProgramsExpand
    • Our Programs
    • Excitotoxicity
    • Autophagy
    • TDP43
  • PatientsExpand
    • ALS Patients
    • A Message of Hope
    • ALS News
  • NewsExpand
    • Press Releases
    • Presentations and Publications
  • CareersExpand
    • Careers
QurAlisQurAlis

Press Releases

Home
News
Press Releases

January 3, 2022

QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

December 22, 2021

QurAlis Announces Publication in Molecular Biology of the Cell of Next Generation Drug Screening Platform for ALS Developed by Company Founders

December 6, 2021

QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND

November 18, 2021

QurAlis to Present at 33rd Annual Piper Sandler Virtual Healthcare Conference

September 14, 2021

QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2

June 8, 2021

Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS

May 26, 2021

QurAlis Boosts World-Class Leadership Team with Addition of Three New Members

February 2, 2021

QurAlis Continues to Expand Leadership Team with Two Key Hires

December 10, 2020

QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models

December 2, 2020

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND

October 29, 2020

QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board

October 7, 2020

QurAlis has won the Amgen Golden Ticket at LabCentral

October 7, 2020

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

October 7, 2020

Discovery Advances

October 7, 2020

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

October 7, 2020

QurAlis wins the Pfizer Golden Ticket!

October 7, 2020

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

October 7, 2020

QurAlis Announces Agreement to Strengthen ALS Pipeline

100 Cambridgepark Drive, 5th Floor
Cambridge, MA 02140, USA
781-816-7031
info@quralis.com

Twitter Linkedin
  • About Us
  • Platform
  • ALS Programs
  • Patients
  • News
  • Careers
Menu
  • About Us
  • Platform
  • ALS Programs
  • Patients
  • News
  • Careers
© 2021 QurAlis Corporation | Privacy Policy | Terms of Use
  • About Us
    • About QurAlis
    • People
    • Partners & Investors
    • Contact Us
  • Platform
    • Antisense Oligonucleotides
    • Patient-derived disease models
    • References
  • ALS Programs
    • Our Programs
    • Excitotoxicity
    • Autophagy
    • TDP43
  • Patients
    • ALS Patients
    • A Message of Hope
    • ALS News
  • News
    • Press Releases
    • Presentations and Publications
  • Careers
    • Careers